Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors
- 76 Downloads
Chromogranin A (CgA) may be prognostic for patients with neuroendocrine tumors; however, the clinical utility of this test is unclear.
Patients undergoing resection for pancreatic neuroendocrine tumors (pNET) were selected from the eight institutions of the US Neuroendocrine Tumor Study Group database. Cox regression was used to identify pre-operative variables that predicted recurrence-free survival (RFS), and those with p < 0.1 were included in a risk score. The risk score was tested in a unique subset of the overall cohort.
In the entire cohort of 287 patients, median follow-up time was 37 months, and 5-year RFS was 73%. Cox regression analysis identified four variables for inclusion in the risk score: CgA > 5x ULN (HR 4.3, p = 0.01), tumor grade 2/3 (HR 3.7, p = 0.01), resection for recurrent disease (HR 6.2, p < 0.01), and tumor size > 4 cm (HR 4.5, p = 0.1). Each variable was assigned 1 point. Risk-score testing in the unique validation cohort of 63 patients revealed a 95% negative predictive value for recurrence in patients with zero points.
This simple pre-operative risk scoring system resulted in a high degree of specificity for identifying patients at low-risk for tumor recurrence. This test can be utilized pre-operatively to aid informed decision-making.
KeywordsChromogranin A Pancreatic neuroendocrine tumor Recurrence Risk score
SMW and DEA are supported with the resources and use of facilities at the William S. Middleton Memorial Veterans Hospital, Madison, WI.
AVF’s position as a research fellow is supported by NIH Surgical Oncology Training Grant (T32 CA090217), and an American College of Surgeons Resident Research Scholarship.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 7.Genç CG, Jilesen AP, Partelli S, Falconi M, Muffatti F, van Kemenade FJ, van Eeden S, Verheij J, van Dieren S, van Eijck CHJ, Nieveen van Dijkum EJM. A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors. Ann Surg. 2018;267:1148–1154.CrossRefGoogle Scholar
- 9.Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, Krenning EP, Bouillon R, Lamberts SW. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997;82:2622–2628.Google Scholar
- 13.Qiu W, Christakis I, Silva A, Bassett RL, Cao L, Meng QH, Gardner Grubbs E, Zhao H, Yao JC, Lee JE, Perrier ND. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. Clin Endocrinol. 2016;85:400–407.CrossRefGoogle Scholar
- 18.Landoni L, Marchegiani G, Pollini T, Cingarlini S, D’Onofrio M, Capelli P, De Robertis R, Davì M V., Amodio A, Impellizzeri H, Malpaga A, Miotto M, Boninsegna L, Crepaz L, Nessi C, Zingaretti CC, Paiella S, Esposito A, Casetti L, Malleo G, Tuveri M, Butturini G, Salvia R, Scarpa A, Falconi M, Bassi C. The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs). Ann Surg. 2017. [Epub] Available from: http://www.ncbi.nlm.nih.gov/pubmed/29189384
- 19.Birnbaum DJ, Turrini O, Vigano L, Russolillo N, Autret A, Moutardier V, Capussotti L, Le Treut Y-P, Delpero J-R, Hardwigsen J. Surgical Management of Advanced Pancreatic Neuroendocrine Tumors: Short-Term and Long-Term Results from an International Multi-institutional Study. Ann Surg Oncol. 2015;22:1000–1007.CrossRefGoogle Scholar
- 20.Tsutsumi K, Ohtsuka T, Fujino M, Nakashima H, Aishima S, Ueda J, Takahata S, Nakamura M, Oda Y, Tanaka M. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification. J Hepatobiliary Pancreat Sci. 2014;21:418–425.CrossRefGoogle Scholar
- 22.Nanno Y, Toyama H, Matsumoto I, Otani K, Asari S, Goto T, Ajiki T, Zen Y, Fukumoto T, Ku Y. Baseline plasma chromogranin A levels in patients with well-differentiated neuroendocrine tumors of the pancreas: A potential predictor of postoperative recurrence. Pancreatology. 2017;17:291–294.CrossRefGoogle Scholar